REG - Avacta Group PLC - Avacta Announces AVA6000 Poster at AACR

AvactaAnnouncement

06/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF7210Fa&default-theme=true

RNS Number : 7210F  Avacta Group PLC  06 March 2024

6 March 2024

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug
Conjugate, AVA6000 to be Presented in a Poster at the American Association of
Cancer Research (AACR) Annual Meeting on April 9, 2024

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, today announces updated
clinical data from the First-in-Human Phase 1 trial of the peptide drug
conjugate, AVA6000 will be presented at the 2024 American Association for
Cancer Research (AACR) Annual Meeting, taking place in San Diego, California
from 5-10 April 2024.  The results will be presented in the Phase 1 Clinical
Trials 2 Poster Session on April 9, 2024 as detailed below.

Presentation details

Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein
(FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide
drug conjugate in patients with FAP-positive solid tumors

Session Title: First-in-Human Phase I Clinical Trials 2

Session Date and Time: Tuesday 9 April 2024 9:00 AM - 12:30 PM

Location: San Diego Convention Center, San Diego CA  USA

Abstract Presentation Number: CT188

First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London,
and The Royal Marsden NHS Foundation Trust

 

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                         www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)         Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland   www.stifel.com (http://www.stifel.com/)

 Peel Hunt (Joint Broker)                                        Tel: +44 (0) 207 418 8900

 James Steel / Chris Golden / Patrick Birkholm                   www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium (Media and IR)                                    avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

 

 

About AVA6000

AVA6000, Avacta Therapeutics' lead oncology program, is a peptide drug
conjugate consisting of doxorubicin conjugated with a peptide moiety that is
specifically cleaved by fibroblast activation protein (FAP) in the tumor
microenvironment (TME). FAP is selectively overexpressed in many solid tumors.
The peptide moiety (pre|CISION(TM)) prevents cellular entry of doxorubicin
unless cleaved by FAP, thus enabling targeted delivery of doxorubicin directly
to the TME.

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

Avacta Group is a UK-based company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics.

 

Avacta has two divisions: an oncology biotech division harnessing proprietary
therapeutic platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division focused on supporting healthcare professionals and
broadening access to testing. Avacta's two proprietary platforms, Affimer®
and pre|CISION™ underpin its cancer therapeutics whilst the diagnostics
division leverages the Affimer® platform to drive competitive advantage in
its markets.

 

The pre|CISION™ platform modifies chemotherapy to be activated only in the
tumour tissue, reducing systemic exposure and toxicity. This is achieved by
harnessing an enzyme called FAP which is highly upregulated in most solid
tumours compared with healthy tissues, turning chemotherapy into a "precision
medicine". The lead pre|CISION™ programme, AVA6000 a tumour activated form
of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in
safety compared with standard doxorubicin, and early signs of clinical
activity.

 

Affimer® is a novel biologic platform which has significant technical and
commercial advantages compared with antibodies and is used both to develop
advanced immunotherapies and to improve the performance of immunodiagnostics.

 

With a balanced business and capital allocation model: a high-value oncology
pipeline supported by a revenue generating, fast-growing diagnostics business,
Avacta seeks to create long-term shareholder value alongside patient benefit.

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFELLBZXLFBBL